A detailed history of J. Goldman & CO LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 33,500 shares of VKTX stock, worth $2.11 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
33,500
Holding current value
$2.11 Million
% of portfolio
0.05%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$10.92 - $16.0 $1.01 Million - $1.48 Million
92,219 New
92,219 $1.02 Million
Q3 2022

Nov 14, 2022

BUY
$2.55 - $3.89 $344,250 - $525,150
135,000 New
135,000 $367,000
Q4 2019

Feb 14, 2020

SELL
$6.38 - $8.73 $82,027 - $112,241
-12,857 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$6.55 - $8.6 $84,213 - $110,570
12,857 New
12,857 $88,000
Q3 2018

Nov 14, 2018

SELL
$9.7 - $19.65 $802,170 - $1.63 Million
-82,698 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$3.88 - $12.74 $320,868 - $1.05 Million
82,698 New
82,698 $785,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.83B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.